India’s 'Thousand Talents' Moment And Models To Shift Gears In R&D
Might Korea, China Successes Provide Ideas?
Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?
You may also be interested in...
Industry leaders and experts, including executives from McKinsey, Eight Roads Ventures and Novartis, share global best practices, insights and expectations around how India could accelerate its journey towards becoming a biopharma innovation hub.
There is momentum for Glenmark’s Ryaltris across new launch markets internationally, with FY2023 and FY2024 seen as important years for revenue scale-up. A partnered nitric oxide nasal spray for COVID-19 faces trial recruitment challenges in India but the firm hopes to be able to debut the product this year.
Scrip takes a look at South Korea’s out-licensing deal trends for 2021, finding that more big transactions are likely as the year moves towards its close despite a wider global slowing in activity, helped by rising innovative R&D.